8-K: Cryoport Reports 10% Revenue Growth in Q1 2025, Driven by Cell & Gene Therapy Demand

Cryoport announces a 10% year-over-year increase in revenue for Q1 2025, reaching $41.0 million, fueled by strong growth in its Life Sciences Services segment and commercial Cell & Gene therapy support.

Summary

• Cryoport reported Q1 2025 revenue from continuing operations of $41.0 million, a 10% increase compared to $37.3 million in Q1 2024.
• Life Sciences Services revenue grew by 17% to $22.9 million, representing 56% of total revenue.
• Commercial Cell & Gene therapy revenue increased by 33% year-over-year.
• The company supported 711 global clinical trials as of March 31, 2025, up from 675 in the previous year.
• Gross margin improved to 45.4% from 40.4% in the prior year.
• Net loss for Q1 2025 was $12.0 million, an improvement from the $18.9 million loss in Q1 2024.
• Adjusted EBITDA was a negative $2.8 million, compared to a negative $6.7 million in the same period last year.
• Cryoport held $244.0 million in cash, cash equivalents, and short-term investments as of March 31, 2025.
• The company is reiterating its full-year 2025 revenue guidance of $165.0 million to $172.0 million, representing 5% to 10% growth year-over-year.
• Cryoport expects the CRYOPDP divestiture to DHL to close in Q2 or Q3 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to revenue growth, improved margins, and strategic partnerships, but tempered by ongoing net losses and external risk factors.

Positives

• Revenue increased by 10% year-over-year, indicating growth in the business.
• Commercial Cell & Gene therapy revenue saw a significant increase of 33%, demonstrating strong performance in a key market segment.
• Gross margin improved from 40.4% to 45.4%, suggesting improved efficiency and profitability.
• Net loss decreased from $18.9 million to $12.0 million, showing progress towards profitability.
• Adjusted EBITDA improved from negative $6.7 million to negative $2.8 million, indicating better operational performance.
• The strategic partnership with DHL is expected to enhance operational reach and reshape the company's competitive profile.
• The company has a strong cash position with $244.0 million in cash, cash equivalents, and short-term investments.
• Cryoport has approximately $73.9 million in total of repurchase authorization available under its two repurchase programs as of March 31, 2025.

Negatives

• The company still reported a net loss of $12.0 million for the quarter.
• Adjusted EBITDA remains negative at $2.8 million, although it has improved year-over-year.
• The company's 2025 guidance is dependent on its current business and expectations, which may be further impacted by factors that are outside of our control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations.

Risks

• The company's performance is subject to economic and geopolitical conditions, supply chain constraints, inflationary pressures, and tariffs.
• The DHL transaction is subject to customary closing conditions, including regulatory approval, and may not close in the expected timeframe or at all.
• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Cryoport is reiterating its revenue guidance for fiscal year 2025, expecting total organic revenue to be in the range of $165.0 million to $172.0 million, representing 5% to 10% growth year-over-year. The company also anticipates a return to positive adjusted EBITDA during 2025.

Management Comments

• Jerrell Shelton, CEO of Cryoport, commented, 'We delivered a strong start to the year with $41.0 million of revenue from continuing operations, which represented 10% year-over-year growth and drove meaningful improvement in adjusted EBITDA.'
• Mr. Shelton also stated, 'We believe order patterns are stabilizing in our Life Sciences Products segment, while engagement levels increased significantly in our Life Sciences Services segment, highlighting a new momentum in our business.'
• Mr. Shelton concluded, 'We remain confident these actions and our momentum will lead us to a return to positive adjusted EBITDA during 2025.'

Industry Context

Cryoport's focus on temperature-controlled supply chain solutions for the life sciences, particularly in the regenerative medicine space, aligns with the growing demand for these services due to the increasing development and commercialization of Cell & Gene-based therapies. The strategic partnership with DHL is a move to enhance its global reach and competitive position in this expanding market.

Comparison to Industry Standards

• While specific competitor data isn't provided, the 10% revenue growth and 33% growth in Cell & Gene therapy revenue suggest Cryoport is performing well in a high-growth sector.
• Companies like BioLife Solutions and Thermo Fisher Scientific also operate in the biopreservation and cold chain logistics space, and their performance metrics could be used as benchmarks.
• The improvement in gross margin and adjusted EBITDA indicates progress towards profitability, a key metric for investors in this industry.

Stakeholder Impact

• Shareholders: Potential for increased value due to revenue growth and strategic initiatives.
• Employees: Opportunity for growth and development within a growing company.
• Customers: Access to enhanced services and innovative products.
• Suppliers: Continued business relationships and potential for increased demand.
• Creditors: Reduced risk due to improved financial performance.

Next Steps

• Complete the CRYOPDP divestiture to DHL, expected in Q2 or Q3 2025.
• Continue to support the increasing number of commercial regenerative medicine products and their rollouts.
• Advance key initiatives such as the IntegriCell Cryopreservation Solution and Global Supply Chain Centers.
• Introduce new innovative products to better serve clients and diversify revenue streams.
• File the Quarterly Report on Form 10-Q with the SEC.

Key Dates

Keywords

Cryoport, Cell & Gene Therapy, Revenue, Financial Results, DHL, CRYOPDP, Clinical Trials, Biologistics, BioStorage, EBITDA